July 24-26, 2017
The platform will bring together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease.
July 24-26, 2017
by Cucunubá ZM, Manne-Goehler JM, Díaz D, Nouvellet P, Bernal O, Marchiol A, Basáñez MG, Conteh L.
Social Science & Medicine, February 2017
Research Research [26 January, 2017]
June 18-20, 2017
GlaxoSmithKline, Tres Cantos, Madrid, Spain
Ben Perry, NTD Drug Discovery Booster Project Manager will be presenting on the NTD Drug Discovery Booster.
April 19-22, 2017
DNDi will be participating at the event.
April 6, 2017
Washington DC, USA
Colin Forsyth, Chagas Epidemiologist at DNDi North America, will be presenting in a session on R&D.
March 24-27, 2017
Charles Mowbray, Head of Drug Discovery at DNDi, will be presenting at the event.
Advances in the treatment and care of patients with Chagas disease
March 10, 2017
Isabela Ribeiro, Dynamic Portfolio Scientific Leader at DNDi, participated at the event.
International Society for Neglected Tropical Diseases Festival
February 23, 2017
London, United Kingdom
James Arkinstall, DNDi‘s Head of Communications & Advocacy, presented on the fundraising campaign for sleeping sickness with the Huffington Post.
KEMRI Annual Scientific and Health Conference
February 8-10, 2017
DNDi participated at the event.
Assessing the health of vulnerable population for an inclusive society
January 29-February 3, 2017
Marc Lallemant, Head of Paediatric HIV Program at DNDi spoke at the event and Jean-Michel Piedagnel, Head of DNDi South East-Asia Regional Office hosted a Q&A session.
by Chatelain E.
Computational and Structural Biotechnology Journal, December 2016
Ärzteblatt [1 December, 2016]
“Mehr Geld für die Forschung zu armutsbedingten Erkrankungen” – “More money for research on poverty-related diseases”
WuXi App Tec [1 December, 2016]
“Harnessing science for the most neglected diseases – A chat with Charles Mowbray, Ph.D., Head of Drug Discovery, DNDi“
KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi
DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.
by Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, ’t Hoen EFM, Wagner AK, Yadav P, Reich MR.
The Lancet, November 2016
by Yang G, Lee N, Ioset JR, No JH.
Journal of Biomolecular Screening, October 2016
The New York Times [27 October, 2016]
“The U.S. is standing in the way of cheaper drugs for the poor”
by Francisco AF, Jayawardhana S, Lewis MD, White KL, Shackleford DM, Chen G, Saunders J, Osuna-Cabello M, Read KD, Charman SA, Chatelain E, Kelly JM.
Scientific Reports, October 2016